

Genetic Basis of the Polymorphisms of the α I Domain of Spectrin

Patrick G. Gallagher, Marc Romana, Clara Wong, and Bernard G. Forget*

Department of Pediatrics, Internal Medicine and Genetics, Yale University School of Medicine, New Haven, Connecticut

Defects of α spectrin have been identified in many cases of hereditary elliptocytosis (HE) and hereditary pyropoikilocytosis (HPP). To aid in the genetic analysis of families with these disorders, the locations of three α -spectrin gene polymorphisms were mapped, the genetic basis of these polymorphisms identified, and PCR-based assays designed for their identification. The frequencies of these polymorphisms were determined in two populations and in patients with α I/50a HE and HPP. These studies identified two distinct haplotypes and provided evidence that two HE/HPP mutations associated with the α I/50a protein phenotype, L207P and L260P, arose on separate chromosomal backgrounds. *Am. J. Hematol.* 56:107–111, 1997. © 1997 Wiley-Liss, Inc.

Key words: spectrin; polymorphism; elliptocytosis; haplotype

INTRODUCTION

The erythrocyte membrane skeleton is responsible for maintaining the shape and deformity of the erythrocyte. Qualitative and quantitative disorders of membrane skeleton proteins have been associated with abnormalities of red blood cell (RBC) shape, including hereditary elliptocytosis (HE) and hereditary pyropoikilocytosis (HPP) [1–4]. HE, characterized by the presence of elliptically shaped erythrocytes in the peripheral blood, is a heterogeneous group of disorders ranging in clinical severity from the asymptomatic carrier state to severe, symptomatic, hemolytic anemia. HPP is an uncommon, severe hemolytic anemia with a characteristic erythrocyte morphology that is reminiscent of that seen in patients after a thermal burn. A number of structural abnormalities of spectrin, the principal component of the erythrocyte membrane skeleton, have been associated with HE and HPP [5–7].

Spectrin is composed of two structurally similar but nonidentical proteins, α and β spectrin. α and β spectrin are composed primarily of homologous 106-amino acid repeats that fold into three antiparallel α -helices connected by short nonhelical segments [8–9]. α and β spectrin combine to form heterodimers, which in turn self-associate to form tetramers and higher order oligomers. These tetramers and oligomers form a lattice-like struc-

ture that is critical for erythrocyte membrane stability as well as erythrocyte shape and deformability. Abnormalities of α spectrin associated with HE and HPP are usually due to mutations in the NH₂-terminus of α spectrin, the α I domain, the region of α spectrin that participates in spectrin heterodimer self-association [5–7].

It is useful to identify genetic markers in the α -spectrin gene to aid in the analyses of patients with these disorders. We have precisely mapped the location of three previously described restriction fragment length polymorphisms, *Xba*I, *Msp*I, and *Pvu*II, in the region of the α -spectrin gene encoding the α I domain of spectrin [10]. These polymorphisms are located in introns and are not related to polymorphisms detected by tryptic mapping of spectrin. The genetic basis of these polymorphisms was determined and polymerase chain reaction (PCR)-based assays developed for their analysis. Using these PCR-based assays, the frequencies of these polymorphisms

M. R.'s current address is Unite de Recherche sur la Drepanocytose, Centre Hospitalier Universitaire, Guadeloupe, French West Indies.

*Correspondence to: Dr. Bernard G. Forget, Hematology Section, Department of Internal Medicine, 333 Cedar Street, P. O. Box 3333, New Haven, CT 06510. Fax: (203) 785-7232. E-mail Bernard.Forget@yale.edu

Received 16 January 1997; Accepted 11 June 1997.




Fig. 1. Location and genetic basis of three polymorphisms of the α I domain of spectrin. **A:** Partial genomic structure of the α I domain of spectrin. The locations of the polymorphic *Xba*I, *Msp*I, and *Pvu*II sites are shown. The locations of primers used in PCR of genomic DNA for polymorphism analysis are indicated by horizontal arrows. **B:** Genetic basis of the polymorphisms of the α I domain of spectrin. The nucleotide sequence of each polymorphism is shown. Comparison of the sequence of allele 1 and allele 2 of the polymorphisms shows the creation or abolition by the different base changes of restriction endonuclease recognition sites for the enzymes *Xba*I, *Msp*I, and/or *Pvu*II.

were determined in two populations and in patients with α I/50a hereditary elliptocytosis and pyropoikilocytosis. These studies identified two distinct haplotypes and provided evidence that two HE/HPP mutations associated with the α I/50a protein phenotype, L207P and L260P, arose on separate chromosomal backgrounds.

MATERIALS AND METHODS

Mapping of a Human α -Spectrin Gene Genomic DNA Clone

A recombinant bacteriophage λ clone containing human genomic DNA corresponding to the α I domain of the α -spectrin gene was isolated from a library of human genomic DNA, partially digested with *Eco*RI, using a synthetic α -spectrin gene fragment as a screening probe.

Mapping

Mapping of genomic DNA by restriction enzyme digestion, Southern blot analysis, and hybridization was carried out according to standard techniques. Restriction

endonucleases were purchased from Boehringer Mannheim (Indianapolis, IN).

Oligonucleotide Primers for Polymerase Chain Reaction

Synthetic oligonucleotides were synthesized using an automated synthesizer (Applied Biosystems, Inc., Foster City, CA) and purified by OPC column chromatography (Applied Biosystems). The location of oligonucleotide primers used in PCR amplification of the α I domain of spectrin is shown in Figure 1. The nucleotide sequences of these primers were as follows:

primer A	5'-CGTGAATTCTGAGAACTAGC
(sense):	AATTAACAG-3'
primer A	5'-CGTGGATCCCCATTAACATT
(antisense):	AACATAAAG-3
primer B	5'-GCGAATTCCTGGGAATGCAA
(sense):	GCAGGAGT-3'
primer B	5'-AGAGCCTAATACAAAGAC-3'
(antisense):	

PCR Amplification of Genomic DNA

Each PCR reaction contained 0.01–0.1 μ g of genomic DNA in a 50- μ l mixture containing 33 ng of each oligonucleotide primer. Amplifications were carried out for 30 cycles in an automated DNA thermal cycler (model 9600; Perkin-Elmer, Roche Molecular Systems, Branchburg, NJ). Each cycle consisted of 30 sec at 94°C, 1 min at 55°C, and 2 min at 72°C, with the last cycle followed by an additional 5 min of extension time at 72°C.

Subcloning of Amplified DNA

Amplification products were subcloned into the pCR2.1 vector (Invitrogen, Carlsbad, CA) using T4 DNA ligase and transformed in competent *Escherichia coli* as directed (TA cloning kit, Invitrogen, La Jolla, CA).

Nucleotide Sequencing of Subcloned, Amplified DNA

Subcloned, PCR-amplified genomic DNA fragments were sequenced using T7 DNA polymerase (Sequenase, United States Biochemical Corp., Cleveland, OH) and the dideoxy chain termination method of Sanger et al. [11].

Patients and Controls

References detailing the clinical and biochemical characteristics of HE and HPP patients with the α I/50a protein phenotype have previously been described [7]. Control genomic DNA was obtained from unrelated individuals from two ethnic groups: non-HE African-Americans (many with various hemoglobinopathies) and Caucasians of Northern European ancestry.

RESULTS

The isolation of the α -spectrin clone λ 3021 from a Charon 4a library of partially *Eco*RI-digested human genomic DNA has been previously described [12]. The genomic structure of the 5' end of the α -spectrin gene has been previously described [13]. The locations of the *Xba*I, *Msp*I, and *Pvu*II polymorphisms were mapped to the locations shown in Figure 1A. These data agree with that of Lecomte et al. [14] who previously localized the *Xba*I polymorphism to the indicated position in intron 2. Restriction enzyme mapping placed the *Msp*I and *Pvu*II polymorphisms very close together.

Nucleotide sequencing of subcloned fragments of genomic DNA identified the precise genetic basis of these polymorphisms (Fig. 1B). In previous studies, all patients homozygous for the presence of the *Msp*I polymorphism were homozygous for the lack of the *Pvu*II polymorphism [15]. Nucleotide sequencing identified the reason for this observation: a single polymorphic nucleotide is the basis for both polymorphisms. Whenever a C is pres-

ent (Fig. 1B), an *Msp*I site is created and a *Pvu*II site is abolished. If an A is present, a *Pvu*II site is created and the *Msp*I site is abolished.

Polymerase chain reaction (PCR)-based assays were developed for the analysis of these polymorphisms. Oligonucleotide primers flanking these polymorphisms were used to amplify genomic DNA by PCR. Amplification products were digested with the appropriate restriction enzyme, *Xba*I, *Msp*I, or *Pvu*II, and subjected to agarose gel electrophoresis.

Amplification of genomic DNA by PCR using primer pair A yielded a band of 360 bp. Digestion of amplification products with *Xba*I followed by electrophoresis in a 3% agarose gel identified fragments of 360 bp (uncut) or 330 bp + 30 bp (Fig. 2). Amplification of genomic DNA by PCR using primer pair B yielded a fragment of 2.5 kb. Digestion of amplification products with either *Msp*I or *Pvu*II followed by electrophoresis in a 1.5% agarose gel identified fragments of 2.5 kb (uncut) or 1.4 kb + 1.1 kb (Fig. 2).

One hundred eight alleles of unrelated individuals from two different genetic backgrounds were analyzed by this PCR-based technique (Table I). The frequencies observed are comparable to those previously reported by Hoffman et al. [10] using genomic Southern blots hybridized to a single-copy probe from the λ 3021 α -spectrin genomic clone. Co-dominant segregation of these polymorphisms was observed in three informative three-generation families.

These studies identified two allelic haplotypes. In all cases, individuals who were homozygous for digestion with *Xba*I, were also homozygous for digestion with *Msp*I and for lack of digestion with *Pvu*II. The converse was also true: all individuals who were homozygous for lack of digestion with *Xba*I were also homozygous for lack of digestion with *Msp*I and for digestion with *Pvu*II. We propose that the *Xba*I (–)/*Pvu*II (+)/*Msp*I (–) allele (GGTTCGAC at the *Pvu*II/*Msp*I site) be considered haplotype 1 and the *Xba*I (+)/*Pvu*II (–)/*Msp*I (+) allele (GGCCGAC at the *Pvu*II/*Msp*I site) be considered haplotype 2. Because the *Xba*I site and the *Pvu*II/*Msp*I site are > 5 kb apart, crossover could theoretically occur, resulting in individuals with genetic haplotypes that cannot be classified as haplotype 1 or haplotype 2. Mapping and partial nucleotide sequence analysis of the λ 3021 α -spectrin genomic clone identified it as haplotype 1.

In many patients with HE and HPP, limited tryptic digestion of spectrin followed by two-dimensional gel electrophoresis has demonstrated abnormal proteolytic cleavage of the 80 kDa peptide of the α I domain of spectrin. Frequently, mutations are found near the site of abnormal proteolytic cleavage [5,16,17]. In HE/HPP patients with one of these proteolytic variants, α I/50a, three different α -spectrin mutations have been identified: L207P, L260P, and S261P [7]. The L207P and L260P




Fig. 2. Analysis of three polymorphisms of the human erythrocyte α -spectrin gene using PCR-based assays. PCR-amplified DNA from three individuals was digested with the restriction endonuclease, *Xba*I, *Pvu*II, or *Msp*I, respectively, and fractionated by agarose gel electrophoresis. A and C: The DNA in lane 1 lacks the polymorphism (–,–); the DNA in lane 2 is heterozygous for the polymorphism (+,–); and the

DNA in lane 3 is homozygous for the polymorphism (+,+). B: Digestion of DNA from the same three individuals with *Pvu*II shows that the DNA in lane 1 is homozygous for the polymorphism (+,+), the DNA in lane 2 is heterozygous for the polymorphism (+,–) and the DNA in lane 3 lacks the polymorphism (–,–). This confirms the *Xba*I/*Msp*I/*Pvu*II haplotypes of –,+,– and +,–,+, respectively (see text for details).

TABLE I. Allelic Frequencies of Three α -Spectrin Gene Polymorphisms*

Restriction endonuclease	Frequency		Fragment sizes of PCR products
	Caucasians	African-Americans	
<i>Xba</i> I	Allele 1: 0.53	Allele 1: 0.47	360 bp
	Allele 2: 0.47	Allele 2: 0.53	330 + 30 bp
<i>Pvu</i> II	Allele 1: 0.47	Allele 2: 0.53	1.4 + 1.1 kb
	Allele 2: 0.53	Allele 2: 0.47	2.5 kb
<i>Msp</i> I	Allele 1: 0.53	Allele 1: 0.47	2.5 kb
	Allele 2: 0.47	Allele 2: 0.53	1.4 + 1.1 kb

*No. of Caucasians = 58; no. of African-Americans = 60.

mutations are common in HE/HPP patients of African descent [2]; the S261P mutation has been identified only in a single Hispanic patient [13]. We analyzed the α I domain polymorphisms in twelve unrelated individuals with α I/50a HE or HPP due to the L207P mutation (7 patients), the L260P mutation (4 patients), or the S261P mutation (1 patient). The distance of these mutations in genomic DNA from the *Msp*I/*Pvu*II polymorphic site is close enough to allow amplification of DNA fragments containing both the mutation and the polymorphic site in a single PCR reaction from each individual. Amplification products were subcloned and individual subclones analyzed for the presence or absence of the mutation and polymorphism. Examination of the data reveals that there are common allelic haplotypes for each mutation, haplotype 1 for the L260P and S261P mutations (4 patients and 1 patient, respectively) and haplotype 2 for the L207P mutation (7 patients) (Table II).

DISCUSSION

These studies demonstrate that the α I domain polymorphisms of spectrin exhibit marked allelic variability

TABLE II. Correlation of Haplotypes and α -Spectrin Mutations in Patients With Hereditary Elliptocytosis and Hereditary Pyropoikilocytosis

Mutation	α I domain haplotype ^a	α II domain haplotype ^b
L154Ins	2	1
L207P	2	1
L260P	1	2
S261P	1	1

^aDefined in Materials and Methods.

^bDefined in reference 18.

in two different populations, making them useful in genetic linkage studies of kindreds with HE and HPP. It also shows that it is unnecessary to perform PCR-based assays for all three polymorphisms to ascertain the status of the α I domain chromosomal haplotype. Excluding crossover between the *Xba*I and the *Pvu*II/*Msp*I polymorphisms which can occur very rarely: (A.-F. Roux, PhD Thesis, University Claude Bernard-Lyon I, 1990), analysis of a single polymorphism should provide sufficient data to deduce the status of the other sites; at the most, *Xba*I and either *Pvu*II or *Msp*I are all that are necessary for determination of a haplotype.

The identification of these polymorphisms permits amplification of a single DNA fragment containing both an α I domain polymorphism and an α I domain HE/HPP mutation, allowing correlation of the polymorphism (and the haplotype) with the mutation, particularly in heterozygous individuals. This is true for α I/50a mutations that occur in either exon 5 or 6, which flank the *Msp*I/*Pvu*II sites, and for α I/74 mutations occurring in exon 2 immediately 5' of the *Xba*I site [5,13]. This will facilitate epidemiologic and population-based genetic studies of HE and HPP mutations in the α -spectrin gene.

The finding of separate allelic haplotypes for each of the two common α I/50a HE/HPP mutations suggests the presence of a “founder effect” for each mutation, i.e., these two mutations arose on separate chromosomal backgrounds. This finding corroborates haplotyping studies of the α II domain polymorphisms of spectrin [18]. The L207P mutation was found only on an α II domain-haplotype 1 allele, whereas the L260P mutation was found only on an α II domain-haplotype 2 allele. Together, these data suggest that the L207P mutation arose on an α -spectrin allele of the α I-haplotype 2/ α II-haplotype 1, and that the L260P mutation arose on an α -spectrin allele of the α I-haplotype 1/ α II-haplotype 2.

These data also corroborate the epidemiological studies of HE-related spectrin mutations and α -spectrin gene polymorphisms in Benin, Africa [19]. The L260P mutation was found in a restricted area of southern Benin among two very closely related ethnic groups, the Fon and the Yoruba. The term “Nigerian allele” was proposed to describe an α -spectrin gene allele containing the L260P HE mutation, the α II-haplotype 2, and two other α -spectrin gene polymorphisms/mutations, R1331I and R1496W. We propose that the α I-haplotype 1 be an additional descriptor of the Nigerian allele.

In a similar manner, it should be noted that the common α I/68 HE phenotype associated with a leucine insertion, L154Ins, only arises on the α I-haplotype 2 α -spectrin gene chromosomal background [15,20].

ACKNOWLEDGMENTS

This work was supported in part by grants from the National Institutes of Health, the March of Dimes Birth Defects Foundation, and the American Heart Association-Connecticut Affiliate.

REFERENCES

1. Palek J, Sahr K: Mutations of the red blood cell membrane proteins: From clinical evaluation to detection of the underlying genetic defect. *Blood* 80:308, 1992.
2. Lux S, Palek J: Disorders of the red cell membrane. In Handin RI, Lux SE, Stossel TP (eds): “Blood: Principles and Practice of Hematology.” Philadelphia: J.B. Lippincott, 1995, p 1701.
3. Lux SE, Becker PS: Hereditary spherocytosis and hereditary elliptocytosis. In Scriver CR, Beaudet AL, Sly WS, Valle D (eds): “The Metabolic and Molecular Bases of Inherited Diseases,” Ed. 7. New York: McGraw-Hill, 1995, p. 3513.
4. Benz ED Jr: The erythrocyte membrane and cytoskeleton: Structure, function and disorders. In Stamatoyanopoulos G, Niehnuis AW, Majerus PW, Varmus H (eds): “The Molecular Basis of Blood Diseases,” Ed 2. Philadelphia: W.B. Saunders, 1994, p 257.
5. Delaunay J, Dhermy D: Mutations involving the spectrin heterodimer contact site: Clinical expression and alterations in specific functions. *Semin Hematol* 30:21, 1993.
6. Maillet P, Alloisio N, Morle L, Delaunay J: Spectrin mutations in hereditary elliptocytosis and hereditary spherocytosis. *Hum Mutat* 8: 97, 1996.
7. Gallagher PG, Forget BG: Hematologically important mutations: Spectrin variants in hereditary elliptocytosis and hereditary pyropoikilocytosis. *Blood Cells Mol Dis*, 22:254, 1996.
8. Winkelmann JC, Forget, BG: Erythroid and nonerythroid spectrins. *Blood* 81:3173–3185, 1993.
9. Gallagher PG, Forget BG: Spectrin genes in health and disease. *Semin Hematol* 30:4, 1993.
10. Hoffman N, Stanislovitis P, Watkins PC, Klinger KW, Linnenbach AJ, Forget BG: Three RFLPs are detected by an alpha spectrin genomic clone. *Nucleic Acids Res* 15:4696, 1987.
11. Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain terminating inhibitors. *Proc Natl Acad Sci USA* 74:5463, 1977.
12. Linnenbach AJ, Speicher DW, Marchesi VT, Forget BG: Cloning of a portion of the chromosomal gene for human erythrocyte α -spectrin by using a synthetic gene fragment. *Proc Natl Acad Sci USA* 83:2397, 1986.
13. Sahr KE, Tobe T, Scarpa A, Laughinghouse K, Marchesi SL, Agre P, Linnenbach AJ, Marchesi VT, Forget BG: Sequence and exon-intron organization of the DNA encoding the α I domain of human spectrin. Application to the study of mutations causing hereditary elliptocytosis. *J Clin Invest* 84:1243, 1989.
14. Lecomte MC, Garbarz M, Grandchamp B, Feo C, Gautero H, Devaux E, Bournier O, Galand C, d’Auriol L, Gailbert F, Sahr KE, Forget BG, Boivin P, Dhermy D: $\text{Sp}\alpha^{178}$: A mutation of the α I spectrin domain in a white kindred with HE and HPP phenotypes. *Blood* 74:1126, 1989.
15. Roux AF, Morle F, Guetarni D, Colonna P, Sahr K, Forget BG, Delaunay J, Godet J: Molecular basis of $\text{Sp}\alpha^{165}$ hereditary elliptocytosis in North Africa: Insertion of a TTG triplet between codons 147 and 149 in the α -spectrin gene from five unrelated families. *Blood* 73: 2196, 1989.
16. Marchesi SL, Letsinger JT, Speicher DW, Marchesi VT, Agre P, Hyun B, Gulati G: Mutant forms of spectrin α -subunits in hereditary elliptocytosis. *J Clin Invest* 80:191, 1987.
17. Coetzer T, Palek J, Lawler J, Liu SC, Jarolim P, Lahav M, Prchal JT, Wang W, Alter BP, Schewitz G, Mankad V, Gallanello R, Cao A: Structural and functional heterogeneity of α -spectrin mutations involving the spectrin heterodimer self-association site: Relationships to hematologic expression of homozygous hereditary elliptocytosis and hereditary pyropoikilocytosis. *Blood* 75:2235, 1990.
18. Gallagher PG, Kotula L, Wang Y, Marchesi SL, Curtis PJ, Speicher DW, Forget BG: Molecular basis and haplotyping of the α II domain polymorphisms of spectrin: Application to the study of hereditary elliptocytosis and pyropoikilocytosis. *Am J Hum Genet* 59:351, 1996.
19. Glele Kakai C, Garbarz M, Lecomte M-C, Leborgne S, Galand C, Bournier O, Devaux I, Gautero H, Zohoun I, Gallagher PG, Forget BG, Dhermy D: Epidemiological studies of spectrin mutations related to hereditary elliptocytosis and spectrin polymorphisms in Benin. *Br J Haematol*, 95:57, 1996.
20. Guetarni D, Roux AF, Alloisio N, Morle F, Ducluzeau MT, Forget BG, Colonna P, Delaunay J, Godet J: Evidence that expression of the $\text{Sp}\alpha^{165}$ hereditary elliptocytosis is compounded by a genetic factor that is linked to the homozygous α -spectrin allele. *Hum Genet* 85:627, 1990.